Compass Pathways’ (CMPS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Compass Pathways (NASDAQ:CMPS) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $70.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley restated an “overweight” rating and set a $17.00 target price on shares of Compass Pathways in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Monday, April 20th. Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday. Royal Bank Of Canada boosted their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, UBS Group set a $18.00 target price on shares of Compass Pathways in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.15.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $13.64 on Wednesday. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm has a fifty day moving average price of $12.01 and a 200 day moving average price of $8.62. The company has a market cap of $1.84 billion, a P/E ratio of -4.33 and a beta of 2.47. Compass Pathways has a 12 month low of $3.45 and a 12 month high of $15.40.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Sell-side analysts predict that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

Large investors have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. increased its position in Compass Pathways by 169.0% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock worth $2,931,000 after buying an additional 266,908 shares during the period. BIT Capital GmbH grew its position in shares of Compass Pathways by 2,963.4% during the fourth quarter. BIT Capital GmbH now owns 288,814 shares of the company’s stock worth $1,993,000 after acquiring an additional 279,386 shares during the last quarter. Eagle Health Investments LP increased its holdings in shares of Compass Pathways by 62.4% in the 4th quarter. Eagle Health Investments LP now owns 1,519,388 shares of the company’s stock valued at $10,484,000 after acquiring an additional 583,938 shares during the period. NEXTBio Capital Management LP purchased a new stake in Compass Pathways in the 4th quarter valued at $5,193,000. Finally, Propel Bio Management LLC boosted its stake in Compass Pathways by 69.0% during the 4th quarter. Propel Bio Management LLC now owns 861,778 shares of the company’s stock worth $5,946,000 after purchasing an additional 351,778 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.